US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Biogen Idec
(NQ:
BIIB
)
219.88
-2.94 (-1.32%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Why Supernus Pharmaceuticals Stock Topped the Market Today
↗
August 03, 2026
It's effecting a "merger of equals" with a peer.
Via
The Motley Fool
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
July 30, 2026
Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion...
Via
StockStory
Why Biogen Stock Topped the Market Today
↗
July 29, 2026
The company published its second-quarter results on Wednesday morning.
Via
The Motley Fool
Biogen Q2 Earnings Call Highlights
↗
July 29, 2026
Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results....
Via
MarketBeat
Topics
Earnings
These S&P500 stocks have an unusual volume in today's session
↗
July 14, 2026
Via
Chartmill
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
July 29, 2026
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP prof...
Via
StockStory
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
July 27, 2026
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for. Biogen beat analysts’ revenue exp...
Via
StockStory
Topics
Artificial Intelligence
3 Profitable Stocks We Steer Clear Of
July 21, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
Biogen Appoints Michael J. Parini as Chief Legal Officer
July 15, 2026
From
Biogen Inc.
Via
GlobeNewswire
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
July 15, 2026
Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to...
Via
StockStory
Topics
Stocks
Discover which S&P500 stocks are making waves on Tuesday.
↗
July 14, 2026
Via
Chartmill
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
↗
July 14, 2026
Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary...
Via
MarketBeat
These S&P500 stocks are moving in today's session
↗
July 14, 2026
Via
Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
↗
July 14, 2026
Via
Chartmill
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
July 14, 2026
From
Biogen Inc.
Via
GlobeNewswire
1 Mid-Cap Stock to Target This Week and 2 We Find Risky
July 14, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Via
StockStory
Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions
↗
July 13, 2026
Energy names help cushion the Dow as oil jumps on U.S.–Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026.
Via
The Motley Fool
Topics
Economy
Stocks
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
July 10, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via
StockStory
2 Fast-Growing Pharmaceutical Stocks to Buy Now
↗
July 08, 2026
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
Via
The Motley Fool
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
↗
July 04, 2026
This could be a key move for future growth.
Via
The Motley Fool
Topics
Intellectual Property
1 S&P 500 Stock with Promising Prospects and 2 We Question
July 02, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via
StockStory
Topics
Energy
Stocks
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
June 29, 2026
From
Block & Leviton LLP
Via
GlobeNewswire
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
June 29, 2026
From
Biogen Inc.
Via
GlobeNewswire
Why Biogen (BIIB) Stock Is Up Today
June 26, 2026
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth sign...
Via
StockStory
Topics
Artificial Intelligence
Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
June 23, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
June 22, 2026
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ...
Via
StockStory
Topics
Artificial Intelligence
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
June 22, 2026
Via
Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
Via
Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
From
BioMedWire
Via
GlobeNewswire
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
June 17, 2026
Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
